Neogen Beats, Raises, and Starts Chipping Away at the Debt

Neogen just gave its turnaround story something it has been missing: numbers. The food-safety company reported adjusted earnings of $0.08 a share on revenue of $222.8 million for its fiscal first quarter — both ahead of Wall Street's expectations — and raised its full-year outlook while chipping away at the debt pile.

The print, reported after Tuesday's close, beat on both lines. Revenue of $222.8 million rose 6.5% from a year earlier and topped the roughly $208.2 million analysts expected. Adjusted earnings of $0.08 a share came in 50% above the $0.05 consensus, per MarketBeat. On a GAAP basis, Neogen posted a net loss of $11.9 million, or $0.05 a share — versus net income of $36.3 million a year earlier, a swing the company said was driven primarily by a non-cash gain from the divestiture of its Cleaners & Disinfectants business in the prior-year quarter.

The quarter in numbers

Both segments grew. Food Safety revenue reached $163.2 million, up 7.4%, with core growth of 8.1%, led by Indicator Testing and Culture Media — including Petrifilm — and Bacterial and General Sanitation. Animal Safety revenue was $59.6 million, up 4.2% with core growth of 8.0%, driven by Veterinary Instruments & Consumables and Biosecurity Products, mostly insect control. Core revenue overall rose 8.1%, though management flagged a roughly 3-percentage-point benefit from distributor inventory adjustments in the prior-year quarter and the timing of customer orders — a tailwind worth remembering when sizing the growth. Domestic revenue was $110.1 million and international $112.7 million, with growth in every region including double-digit gains in Asia Pacific.

The guide

The company raised its fiscal 2027 outlook: revenue of $885 million to $890 million, up from $880 million to $885 million, and adjusted EBITDA of $181 million to $183 million, up from $180 million to $182 million. Management expects first-half core growth of about 3.5%, with operational-efficiency gains supporting margin improvement in the second half — and said duplicative costs should peak and then decline, with potential operational improvements of 200 to 300 basis points beginning in fiscal 2029.

Fixing the balance sheet

The other half of the story is leverage. Neogen repaid $30 million of term debt in the quarter and expects its planned genomics divestiture to generate roughly $140 million in additional proceeds for further debt reduction. Free cash flow came in at $4.7 million, up about $18 million from a year earlier, and adjusted EBITDA margin expanded 170 basis points to 18.7% on $41.6 million of adjusted EBITDA. Gross margin improved to 47.4% from 45.4%, driven mostly by lower costs tied to the former 3M Food Safety integration.

Petrifilm comes home

Neogen is also on track with its Petrifilm manufacturing move: the first stock-keeping unit was fully validated in August, and the multi-quarter transition to its Lansing site begins in November. Separately, the company announced a strategic collaboration with — and an equity investment in — Hinalea Imaging to develop digital imaging tools for food-safety inspection. CEO Mike Nassif said the company is shifting “from strengthening fundamentals to scaling them.”

The stock

Investors needed a minute. Shares fell 8.07% to $11.96 in Tuesday's regular session, then reversed sharply once the numbers crossed, with extended-trading quotes early Wednesday running well above the close, per MarketBeat. The snap-back says something about expectations into the print: the bar was low, and Neogen cleared it with room.

TickerGrove's read: the quality caveat is the roughly 3 points of order-timing benefit inside that 8.1% core growth. Strip it out and the quarter is still a solid beat — and the durable signals (debt paydown, margin expansion, the Petrifilm timeline) are the things that still matter when the timing benefit rolls off.